IgA and IgM-enriched Immunoglobulins in Primary Immunodeficiencies: a Pilot Study.

ABSTRACT:

Purpose

Despite well-conducted replacement therapy with polyvalent immunoglobulins (IgRT), some patients with primary immunodeficiencies (PID) continue to experience recurrent or chronic infections. IgA and IgM, essential for mucosal and complement-mediated immunity, are absent or minimal in standard immunoglobulin products. The aim of this study is to evaluate the safety and clinical evolution profiles in PID patients with undetectable IgA/IgM levels and persistent infections despite standard IgRT, after introduction of an IgA- and IgM-enriched immunoglobulin preparation (IgGAM, Pentaglobin^®).

Methods

A compassionate use program (CUP) in France enrolled 20 PID patients with undetectable IgA/IgM levels, receiving IgGAM IV infusions every 7-14 days. Tolerance, infe

SUBMITTER: Collet A 

PROVIDER: S-EPMC12783217 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature